Innovative Mental Health Focus Wesana Health operates at the forefront of psychedelic medicine for mental health treatment, presenting opportunities to collaborate on innovative therapies and expand into emerging mental health markets.

Recent Asset Acquisition The acquisition of SANA-013 assets by Lucy Scientific Discovery highlights potential opportunities to engage with entities interested in psychedelic therapeutics and related biotech developments.

Strategic Partnerships Partnerships with major players like Tyson Foods indicate openness to collaborations aiming to destigmatize plant medicines, opening doors for co-developing educational and wellness programs with health and wellness brands.

Research and Development Expansion Collaboration with the University of South Carolina on the BrainStorm Lab underscores opportunities to offer research grants, joint ventures, and consulting services focused on traumatic brain injuries and neurotherapeutics.

Growth and Funding Potential With recent funding of 13 million dollars and a strategic focus on psychedelic medicine, Wesana presents scalable opportunities for investors and partners interested in early-stage biotech and mental health solutions.